Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The Haematological Malignancy Patient-Reported Outcome (HM-PRO) is a validated tool, assessing symptom burden and impact of disease on QoL, comprisimg Part-A (physical, social well-being, emotional behaviour, eating/drinking habits) and Part-B (symptoms)
Exxuas label includes a boxed warning for suicidal thoughts and behaviors in children and young adults, for whom the drug is not approved
However the study impact of RT-CGM in hospitalized patients remains limited
Those two compounds alone have never been shown to have any benefit to justify them being used therapeutically in humans, says Taylor
US$ 24.25
US$ 25.92
US$ 23.54
